IFU 0053081 EN

AKIT-ABC-RAD-01

2023 - OCT 02

Dual Strip Antigen Test for (Covid-19 + Flu A + Flu B) + RSV + ADV (Ag) - Instructions For Use (IFU)

For in vitro diagnostic use only.

Sample Collection Method

Intended Use

The assaya ABC-RAD Flu, COVID-19, Respiratory syncytial virus (RSV), and Adenovirus (ADV) Antigen Rapid Test is a rapid immunochromatographic assay intended for the qualitative detection of antigens from influenza type A, type B, SARS-CoV-2, RSV, and ADV viruses in nasal secretion from symptomatic individuals. This test is intended for in vitro diagnostic use. This test is easy to perform and results can be interpreted in 10 minutes.

Antigens from influenza type A, type B, SARS-CoV-2, RSV, and ADV viruses is generally detectable in upper respiratory samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results are presumptive, and confirmation with a molecular assay, if necessary, for patient management may be performed. Negative results do not rule out influenza type A, type B, SARS-CoV-2, RSV, and ADV virus infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms. The assaya ABC-RAD Flu, COVID-19, RSV, and ADV Antigen Rapid Test is intended for use by medical professionals or trained operators who are proficient in performing tests and trained clinical laboratory personnel.

Materials

Each box contains 100 test kits. Each test kit contains:

1 Nasal SWAC – Sterile Wood Abrasive Collector
1 Spacket with Activator: Sodium Azide(<0.1%); Sodium Hydroxide(<0.5%); Albumin Bovine Serum(<1%)
1 Test Indicator

Storage And Disposal

The product should be stored at 15-30℃ , away from direct sunlight. Do not freeze or overheat the test kit or kit reagents. Kit contents are stable until the expiration date printed on the outer box. The indicators must be kept in the foil pouch until use. Dispose of used contents in accordance with federal, state, and local requirements.

Sample Preparation

Before use, check the expiration date of the packaging. If the kit is past its expiration date, do not use. Confirm that all components needed are in the kit.

Stand up the spacket, and tear it open. Be careful not to spill the liquid inside.

Obtain the sterile SWAC. Make sure the SWAC head does not touch anything until sample collection.

Insert the SWAC into the nostril that presents the most secretions under visual inspection. Keep the SWAC near the septum floor of the nose in the nasal anterior. Rotate the SWAC 5 times in each nostril.

Assay Procedure

Put the SWAC into the spacket. Roll the swab 5 times. Leave the SWAC in the spacket for 1 minute before inserting the test indicator.

While the SWAC remains in the spacket, place the test indicator into the spacket with the droplets going down. Leave the test indicator in the spacket for 10 minutes.

10 Minutes

Take out the test indicator and read the result at 10 minutes. Do not read the result after 20 minutes. To confirm the result, the test indicator may also be read by the intelligent analyzer eXpress (iaX-2101) after 10 minutes.

Result Interpretation

Positive Indicator Line Legend

Negative

Invalid

Positive Results

At 10 minutes, the appearance of the Control Line and ANY shade of Test Line (Flu A, Flu B, COVID-19, RSV, and ADV area) on the Test Indicator, indicates a positive result for the presence of Influenza type A, B, SARS-CoV-2, RSV, and/or ADV viral antigen.

Please refer to the Indicator Line Legend to interpret the test lines.

Negative Results

At 10 minutes, if only Control Line area shows a line, it means a negative result. A negative result indicates that the presence of influenza type A, influenza type B, SARS-CoV-2, RSV, and ADV viral antigen is negative in the specimen, or the antigen level is below the detection limit.

Invalid Results

If after 10 minutes, the Control Line does not appear, even if any Test Line appears, the result is considered invalid. When invalid, a new test must be performed with a freshly collected specimen sample.

Internal Controls

Two internal procedural controls are needed to confirm correct assay procedure and active kit components. One of two is a line appearing in the “Control Line” area in every run of the test to assess validity of the test. Another one is a clear background serving as an internal negative control. The background color should be white and not interfere with the reading of the test.

Result Interpretation with the iaX-2101

Please refer to the full iaX-2101 Instructions for Use for complete instructions on how to operate the IaX.

Place the test indicator into the iaX-2101, with the barcode pointing in.

A Green ( – ) indicates a negative result for the presences of Flu A, Flu B, SARS-CoV-2, RSV, and ADV antigen or that the antigen level is below the detection limit.
A Yellow ( ! ) indicates that the test is invalid and a new test must be performed with a freshly collected specimen sample.
A Red ( + ) indicates a positive result for the presences of Flu A, Flu B, SARS-CoV-2, RSV, and/or ADV antigen.

GREEN – (NEGATIVE)

YELLOW ! (INVALID)

RED + (POSITIVE)

Warnings & Precautions

For in vitro diagnostic use.
Directions should be read and followed carefully.
Do not use the kit contents beyond the expiration date printed on the outside of the box.
Do not interchange or mix different lots of reagents.
Disregard test results beyond specified time (20 min).
Use appropriate precautions in the collection, handling, storage, and disposal of patient samples and used kit contents.
Use of Nitrile or Latex gloves is recommended when handling patient samples.
Dispose of containers and used contents in accordance with Federal, State and Local requirements.
Do not reuse kit components or test devices.
The Test Indicator must remain sealed in the protective foil pouch until use.
To obtain accurate results, you must follow the Package Insert.
Inadequate or inappropriate specimen collection, storage, and transport may yield false test results.
Seek specific training or guidance if you are not experienced with specimen collection and handling procedures.

Product Limitations

The contents of this kit are to be used for the qualitative detection of Flu A, Flu B, SARS-CoV-2, RSV, & ADV antigen by Sterile Wood Abrasive Collector (SWAC). For quantitative detection of the assay, use the iaX-2101. Please refer to the iaX-2101 IFU for full instructions on using the iaX-2101.
Positive test results do not rule out co-infections with other pathogens.
Negative test result do not rule out influenza type A, type B, SARS-CoV-2, RSV, and ADV viral infections. Negative results should be confirmed by molecular test.
A negative test result may occur if the level of antigen in a sample is below the detection limit of the test.
Failure to follow the test procedure and interpretations of test results may adversely affect test performance and/or invalidate the test results.
Test results must be evaluated in conjunction with other clinical data available to the physician.
Antibodies may fail to detect, or detect with less sensitivity, when influenza type A, type B, SARS-CoV-2, RSV, or ADV viruses that have undergone minor amino acid changes in the target epitope region.

Limit of Detection (LoD)

The limit of detection (LoD) for the assaya ABC-RAD Flu, COVID-19, RSV, and ADV Antigen Rapid Test was established in an analytical sensitivity study performed in clinical nasal matrix. The LoD concentrations identified for each strain tested are listed in the table below.

Interference

Nasal spray products, hemoglobin, and common chemicals were evaluated and did not interfere with the assaya ABC-RAD Flu, COVID-19, RSV, and ADV Antigen Rapid Test in clinical nasal matrix at the levels tested below.

Cross Reactivity

The cross-reactivity of the assaya ABC-RAD Flu, COVID-19, RSV, and ADV Antigen Rapid Test was performed on the positive and negative clinical matrix containing high levels of non-target microorganisms. Bacteria was tested at a target concentration between 106 and 1010 cfu/mL and viruses were tested at concentrations between 105 and 108 TCID50/mL (or pfu/mL). No cross-reactivity or interference was seen when tested at the potentially interfering concentrations. The bacteria and viruses tested were listed in the table below.

References

Murphy B.R. and Webster R.G., 1996, Orthomyxoviruses, pp. 1397–1445. In: Fields Virology, 3rd edition, B.N. Fields, D.M. Knipe, P.M.Howley, et al. (eds.), Lippincott-Raven, Philadelphia.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. (15 February 2020). “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. The Lancet. 395 (10223): 507–513.
Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. (February 2020). “Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods”. Acta Pharmaceutica Sinica B. doi:10.1016.
“How to Protect Yourself & Others”. Centers for Disease Control and Prevention (CDC). 8 April 2020. Archived from the original on 26 February 2020. Retrieved 9 April 2020.
Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med.360(6),588– 598 (2009).
Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respirator y infections due to respirator y syncytial virus in young children: a systematic review and meta-analysis. Lancet. 375(9725),1545–1555 (2010).
Englund. J.A., P. A. Peidra, A. Jewell, K. Patel, B. B. Baxter and E. Whimbey. 1996. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J. Clin. Microbiol. 34:1649- 1653.
Crowcroft, N.S., F. Cutts and M.C. Zambon. 1999. Respiratory syncytial virus: an underestimated cause of respiratory infection, with prospects for a vaccine. Commun Dis Public Health. 2: 234-241.
Barenfanger, J., C. Drake, N. Leon, T. Mueller and T. Troutt. 2000. Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study. J. Clin. Microbiol. 38:2824-2828.
Biosafety in Microbiological and Biomedical Laboratories, 5th Edition. U.S. Department of Health and Human Services, CDC, NIH, Washington, DC (2007).